康希诺生物(6185.HK)一度大涨超16.8%，最高触及55.7港元，创2023年3月以来新高；A股一度涨超11%，最高触及92.7元，创2023年8月以来新高。 据市场人士分析，近期，世界卫生组织针对蚊媒传播疾病基孔肯雅热发出预警信号，刺激了疫苗板块的市场情绪。根据广东省疾控局8月3日发布的数据，7月27日0时至8月2日24时，广东全省新增报告2892例基孔肯雅热本地病例。 另外，今年下半年以来，康希诺旗下多款产品研发及商业化取得重要进展。其中，康希诺生物上月公布，公司研发的重组三价嵴髓灰质炎疫苗(Sf-RVN细胞)已获得中国国家药品监督管理局批准，可以开展相关临床试验。6月20日，康希诺生物发布公告，中国国家药品监督管理局已批准公司研发的13价肺炎球菌多糖结合疫苗(CRM197╱破伤风类毒素)的新药上市申。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.